EUCTR2009-012567-33-SK进行中（未招募）不适用
A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who are able to provide written informed consent (as required by IRB/IEC), prior to the initiation of any protocol-required procedures.
- •2. Ability, in the opinion of the principal investigator, to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, and discontinuation of prohibited concomitant medication, and to be reliably rated on assessment scales.
- •3. Subjects with a stable living environment when not in hospital, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s).
- •4. Male and female subjects 18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria and confirmed by the M.I.N.I. for Psychotic Disorders
- •5. Subjects who have been recently hospitalized (ie, < 14 days prior to Screening) or who would benefit from hospitalization for treatment of a current acute relapse of schizophrenia at study entry.
- •6. Subjects who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by a PANSS Total Score = 80 AND CGI-S score =4 (moderately ill) at the Screening and Baseline visit.
- •7. Subjects who have received previous outpatient antipsychotic treatment at an adequate dose for an adequate duration and who showed a previous response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the investigator’s opinion.
- •8. Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.
- •9. Subjects willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and during the study period
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Sexually active males or females of child-bearing potential who are not practicing two different, acceptable (as defined by the protocol) methods of birth control during the study and for the prescribed periods after last dose of study drug.
- •2. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
- •3. Subjects presenting with a first episode of schizophrenia based on the clinical judgment of the investigator.
- •6. Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia (see protocol for details).
- •8. Subjects with a significant risk of violent behaviour; who represent a risk of committing suicide as indicated by any suicidal ideation within the last 6 months or any suicidal behaviour within the last two years; or who in the clinical judgment of the investigator present a serious risk of suicide.
- •18. Patients having laboratory test and ECG results outwith limits prescribed in the protocol.
- •25. Subjects who participated in a clinical trial within the last 180 days or who participated in more than two clinical trials within the past year.
- •26. Any subject who, in the opinion of the investigator, should not participate in the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute SchizophreniaschizophreniaMedDRA version: 12.0Level: LLTClassification code 10001064Term: Acute schizophreniaEUCTR2009-012567-33-BGOtsuka Pharmaceutical Development & Commercialization, Inc.450
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia.CTRI/2009/091/000952Otsuka Pharmaceutical Development Commercialization Inc450
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Major Depressive DisorderEUCTR2019-004264-21-DEBoehringer Ingelheim Pharma GmbH & Co. KG431
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Depressive DisorderMedDRA version: 20.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 100000004873EUCTR2019-004264-21-HUBoehringer Ingelheim RCV GmbH & Co KG431
招募中
2 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Major Depressive DisorderJPRN-jRCT2080225310Boehringer Ingelheim431